Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KEAP1 | Q14145 | 1/20 | 0.48 |
| ▸ | AKR1C3 | P42330 | 1/20 | 0.48 |
| ▸ | KMO | O15229 | 1/20 | 0.45 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.43 |
| ▸ | PPARG | P37231 | 2/20 | 0.41 |
| ▸ | NPC1 | O15118 | 2/20 | 0.40 |
| ▸ | POLB | P06746 | 1/20 | 0.40 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.40 |
| ▸ | RAB9A | P51151 | 1/20 | 0.40 |
| ▸ | GRIA2 | P42262 | 5/20 | 0.40 |
| ▸ | FAAH | O00519 | 1/20 | 0.40 |
| ▸ | NR1H4 | Q96RI1 | 1/20 | 0.39 |
| ▸ | MRGPRX4 | Q96LA9 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL760980 | 0.89 | AKR1C3 (0.48) | AKR1C3KMOKDM4EPPARGNPC1 | |
| SCHEMBL753235 | 0.87 | KEAP1 (0.60) | KEAP1GRIA2 | |
| SCHEMBL783111 | 0.86 | KEAP1 (0.43) | KEAP1KDM4ENPC1POLBCYP2C9 | |
| SCHEMBL756185 | 0.85 | KEAP1 (0.44) | KEAP1AKR1C3PPARGNPC1RAB9A | |
| SCHEMBL757862 | 0.83 | KEAP1 (0.40) | KEAP1KDM4ENPC1POLBRAB9A | |
| SCHEMBL757860 | 0.83 | KEAP1 (0.40) | KEAP1KDM4ENPC1POLBRAB9A | |
| SCHEMBL762296 | 0.83 | GRIA2 (0.55) | KEAP1NPC1RAB9AGRIA2 | |
| SCHEMBL1972444 | 0.79 | AKR1C3 (0.50) | AKR1C3KMOKDM4ENPC1POLB | |
| SCHEMBL783110 | 0.77 | MAPT (0.42) | KDM4ENPC1POLBRAB9A | |
| SCHEMBL757752 | 0.76 | KEAP1 (0.42) | KEAP1KDM4ENPC1RAB9AGRIA2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8569285-B2 | Dihydrobenzoxathiazepine compounds, a process for their preparation and pharmaceutical compositions containing them | LES LABORATOIRES SERVIER (FR) | 2013-10-29 | — | — | US | disclosed |
| EP-2431360-B1 | Derivatives of dihydrobenzoxathiazepine, method of preparing same and pharmaceutical compositions containing them as well as their uses as modulators of AMPA receptors | SERVIER LAB (FR) | 2013-04-17 | — | — | EP | disclosed |
| US-20120071462-A1 | Dihydrobenzoxathiazepine compounds, a process for their preparation and pharmaceutical compositions containing them | LES LABORATOIRES SERVIER (FR) | 2012-03-22 | — | — | US | disclosed |
| WO-2012035216-A1 | DIHYDROBENZOXATHIAZEPINE DERIVATIVES, PREPARATION THEREOF, PHARMACEUTICAL COMPOSITIONS AND USE AS AMPA RECEPTOR MODULATORS | LES LABORATOIRES SERVIER (FR) | 2012-03-22 | — | — | WO | disclosed |
| EP-2431360-A1 | Derivatives of dihydrobenzoxathiazepine, method of preparing same and pharmaceutical compositions containing them as well as their uses as modulators of AMPA receptors | Les Laboratoires Servier (FR) | 2012-03-21 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120071462-A1 | Dihydrobenzoxathiazepine compounds, a process for their preparation and pharmaceutical compositions containing them | GABRA1, GRM1, GABRA5 | KEAP1 2482/4885AKR1C3 844/4885KMO 303/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.